Cellectis (NASDAQ:CLLS) Lowered to “Hold” at Zacks Investment Research

Cellectis (NASDAQ:CLLSGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Monday, Zacks.com reports.

According to Zacks, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. “

CLLS has been the topic of several other research reports. Robert W. Baird upgraded shares of Cellectis from a “neutral” rating to an “outperform” rating and set a $10.00 price target on the stock in a research report on Wednesday, May 18th. They noted that the move was a valuation call. StockNews.com upgraded shares of Cellectis from a “sell” rating to a “hold” rating in a research report on Wednesday, May 18th. Finally, Barclays reduced their price target on shares of Cellectis from $9.00 to $7.00 in a research report on Friday, May 13th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $17.14.

Shares of Cellectis stock traded down $0.09 on Monday, hitting $3.69. 37,823 shares of the company traded hands, compared to its average volume of 255,300. The stock has a market capitalization of $167.86 million, a P/E ratio of -1.25 and a beta of 2.24. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.73 and a current ratio of 3.73. Cellectis has a 52 week low of $2.85 and a 52 week high of $16.53. The business has a 50-day simple moving average of $3.99 and a 200 day simple moving average of $6.03.

Cellectis (NASDAQ:CLLSGet Rating) last announced its quarterly earnings results on Thursday, March 3rd. The biotechnology company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.50. Cellectis had a negative net margin of 312.64% and a negative return on equity of 53.48%. The company had revenue of $13.66 million for the quarter, compared to analysts’ expectations of $12.30 million. During the same quarter in the previous year, the business posted ($0.95) earnings per share. Research analysts expect that Cellectis will post -2.19 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of the business. OLD Mission Capital LLC purchased a new stake in shares of Cellectis during the third quarter valued at $253,000. Deutsche Bank AG purchased a new stake in shares of Cellectis during the third quarter valued at $42,000. BlackRock Inc. boosted its stake in shares of Cellectis by 5.9% during the third quarter. BlackRock Inc. now owns 312,256 shares of the biotechnology company’s stock valued at $3,937,000 after purchasing an additional 17,387 shares during the period. US Bancorp DE boosted its stake in shares of Cellectis by 94.0% during the third quarter. US Bancorp DE now owns 2,332 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,130 shares during the period. Finally, Prosight Management LP boosted its stake in shares of Cellectis by 1.2% during the third quarter. Prosight Management LP now owns 87,103 shares of the biotechnology company’s stock valued at $1,098,000 after purchasing an additional 1,067 shares during the period. Institutional investors and hedge funds own 40.55% of the company’s stock.

Cellectis Company Profile (Get Rating)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

Recommended Stories

Get a free copy of the Zacks research report on Cellectis (CLLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.